The DOI matches its Crossref record.
Adoptive cellular immunotherapy for EBV lymphoproliferative diseases
Abstract
Summary: Reactivation of EBV (Epstein‐Barr virus) after bone marrow transplantation can result in EBV‐associated lymphoproliferative disease (EBV‐LPD), We have administered donor‐derived EBV‐specific cytotoxic T lymphocytes (CTL) to patients who are at high risk of this complication after receiving a T‐cell‐depleted allograft from a matched unrelated or mismatched related donor. The cells were marked with (he neo GENE U fore infusion so that we could evaluate their persistence and efficacy, CTL infusion produced a virus‐specific immune response to EBV that persisted for up to 2 years. None of the 36 patients who received prophylactic CTLs have developed EBV‐LPD compared with a cumulative risk of 14% in patients who did not receive this treatment. Strong evidence of clinically valuable immune activity conies from 6 of these 36 patients whose pre‐CTL levels of EBV DNA were elevated to a degree strongly predictive of the onset of lymphoma. In each of these cases, the levels returned to baseline after CTL infusion. 2 patients who were treated for clinically evident EBV‐LPD attained prolonged remission after CTL infusion and in situ hybridization and semiquantitative PCR showed that the gene‐marked CTL had selectively accumulated at disease sites, The prophylactic CTL treatment lacked acute adverse effects, whereas 1 patient who received CTLs for bulky established disease developed initial tumor swelling and respiratory obstruction. We conclude that EBV‐specific CTLs are a safe and effective prophylaxis for EBV lymphoma and can also eradicate established disease. This approach is now being extended lo other viruses that produce post‐trans‐plant morbidity and to other EBV‐associated malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D.-K., Bowman, L. C., Krance, R. A., Brenner, M. K., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1549 · Cited by 1,135
Self-citationAdoptive T cell therapy for cancer in the clinic
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32446 · Cited by 553
Post-Transplant Malignancy: The Role Of Immunosuppression
Penn, I. (2000) · Drug Safety · doi:10.2165/00002018-200023020-00002 · Cited by 414
Hegde, M., Corder, A., Chow, K. K., Mukherjee, M., Ashoori, A., Kew, Y., Zhang, Y. J., Baskin, D. S., Merchant, F. A., Brawley, V. S., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.185 · Cited by 373
Self-citationChimeric Antigen Receptor Therapy for Cancer
Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-060512-150254 · Cited by 349
Metadata
- Authors
- Heslop, H. E., & Rooney, C. M.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 1997-06
- Volume
- 157
- Issue
- 1
- Pages
- 217-222
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2141099302
- Cited by
- 205
- References
- 0
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adoptive cellular immunotherapy for EBV lymphoproliferative diseases. https://app.cochat.ai/papers/10.1111/j.1600-065x.1997.tb00984.x
- The paper
- Heslop, H. E., & Rooney, C. M. (1997). Adoptive cellular immunotherapy for EBV lymphoproliferative diseases. Immunological Reviews. https://doi.org/10.1111/j.1600-065x.1997.tb00984.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.